|
Clinical features of type 2 diabetes and control groups |
|||
| Control subjects |
Type 2 diabetes |
P |
|
|
|
|||
| N |
22 |
10 |
|
| Age (years) |
61.5 ± 5.5 |
62.2 ± 7.5 |
P = 0.76 |
| M:F |
15:7 |
8:2 |
|
| Diabetes duration (years) |
- |
6.5 (7.75) |
|
| BMI (kg/m2) |
26.6 ± 4.5 |
28.1 ± 6.9 |
P = 0.46 |
| HbA1c (%) |
- |
6.9 ± 0.7 |
|
| Systolic blood pressure(mmHg) |
145.8 ± 21.8 |
144.7 ± 16.9 |
P = 0.88 |
| Diastolic blood pressure(mmHg) |
89.6 ± 11.3 |
80.1 ± 9.3 |
P = 0.03 |
| Statin use (n) |
5 |
9 |
P = 0.0005 |
| ACE inhibitors (n) |
2 |
4 |
P = 0.05 |
| Aspirin (n) |
3 |
6 |
P = 0.01 |
|
Data are means ± SD or median (interquartile range). BMI – body Mass Index HbA1c – glycosylated hemoglobin | |||
Kejariwal et al. BMC Endocrine Disorders 2008 8:12 doi:10.1186/1472-6823-8-12 |
|||